APP Pharmaceuticals receives FDA approval to market Sumatriptan Succinate Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Sumatriptan Succinate Injection, USP, in two dosage strengths. Sumatriptan Succinate Injection is therapeutically equivalent to the reference-listed drug Imitrex®, which is marketed by the innovator GlaxoSmithKline.

APP will package Sumatriptan Succinate Injection in pre-filled syringes of 4 mg (base) /0.5 mL and 6 mg (base) / 0.5 mL. In February 2009, APP received approval for Sumatriptan Succinate for Injection, USP packaged in single dose vials of 6 mg / 0.5 mL.

APP's Sumatriptan Succinate Injection is AP-rated, bar-coded and latex-free. According to IMS data, 2008 sales of this product in the United States were approximately $241 million1. Syringe cartridges and refills accounted for more than $218 million1.

“The launch of this important migraine medication in pre-filled syringes provides APP customers with a full product line of dosages and strengths for generic Sumatriptan,” said Thomas H. Silberg, president and chief executive officer of APP Pharmaceuticals.

Sumatriptan Succinate Injection is a vascular headache suppressant indicated for the acute treatment of migraine attacks with or without aura and the acute treatment of cluster headache episodes. The American Migraine Study II estimated that as many as 28 million Americans suffer from migraine headaches.

Source: APP Pharmaceuticals, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Curcumin-based inhibition of thiol isomerases: A potential treatment for food allergies